IL15 and neoplasm: designed GPC3 CAR-T cells co-expressing IL-15 and IL-21 and observed robust expansion and sustained persistence of these T cells in their HCC xenograft models; the resulting tumor control and survival rates were higher than those with CAR-T cells equipped with only one cytokine or the other (45).